Chan Patrick G, Kumar Akshay, Subramaniam Kathirvel, Sanchez Pablo G
University of Pittsburgh, Pittsburgh, PA, USA.
Semin Cardiothorac Vasc Anesth. 2020 Mar;24(1):34-44. doi: 10.1177/1089253220905147. Epub 2020 Feb 8.
End-stage lung disease is ultimately treated with lung transplantation. However, there is a paucity of organs with an increasing number of patients being diagnosed with end-stage lung disease. Ex vivo lung perfusion has emerged as a potential tool to assess the quality and to recondition marginal donor lungs prior to transplantation with the goal of increasing the donor pool. This technology has shown promise with similar results compared with the conventional technique of cold static preservation in terms of primary graft dysfunction and overall outcomes. This review provides an update on the results and uses of this technology. The review will also summarize clinical studies and techniques in reconditioning and assessing lungs on ex vivo lung perfusion. Last, we discuss how this technology can be applied to fields outside of transplantation such as thoracic oncology and bioengineering.
终末期肺病最终需通过肺移植进行治疗。然而，随着越来越多的患者被诊断为终末期肺病，可供移植的器官却很匮乏。体外肺灌注已成为一种潜在工具，可在移植前评估边缘供肺的质量并对其进行修复，目的是增加供肺库。与传统的冷静态保存技术相比，这项技术在原发性移植物功能障碍和总体结果方面显示出了前景，取得了类似的效果。本综述提供了关于该技术的结果和应用的最新情况。该综述还将总结在体外肺灌注中对肺进行修复和评估的临床研究及技术。最后，我们将讨论这项技术如何应用于移植以外的领域，如胸科肿瘤学和生物工程。
